Bharat Biotech to have phase 3 efficacy data for Covaxin in 2 weeks

The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials. Ella also said the intra-nasal vaccine candidate was set to start phase 1 trials later this week.

Read more

Show More

Related Articles

Back to top button